MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacira BioSciences DIO Ratio 2011-2025 | PCRX
Annual DIO Ratio Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 246 | 198 | 178 | 212 | 191 | 199 | 204 | 172 | 104 | 313 | 138 | 104 | 137 | 27.1 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 313 | 27.1 | 173 |
Quarterly DIO Ratio Pacira BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 407 | 315 | 344 | - | 253 | 206 | 194 | - | 217 | 175 | 176 | - | 87.2 | 93.4 | 256 | - | 174 | 168 | 188 | 167 | 197 | 264 | 189 | 167 | 238 | 211 | 179 | 185 | 232 | 212 | 179 | 177 | 207 | 159 | 135 | 121 | 66.1 | 124 | 209 | 290 | 354 | 297 | 236 | 34.5 | 131 | 134 | 113 | 77.2 | 96 | 139 | 111 | 114 | 119 | 165 | 93.6 | - | 33.8 | 36.5 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 407 | 33.8 | 178 |
DIO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
58.7 | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
347 | $ 0.73 | -3.6 % | $ 51.9 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
459 | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
167 | $ 1.7 | -2.59 % | $ 183 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
133 | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
48.9 | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
221 | $ 3.07 | -6.25 % | $ 1.6 B | Canada |
 |
Agile Therapeutics
AGRX
|
82.7 | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
1.35 K | $ 5.11 | -5.46 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
71.9 | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
703 | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
460 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
149 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
100 | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
176 | $ 12.37 | 8.32 % | $ 633 M | USA |
 |
Evoke Pharma
EVOK
|
995 | $ 10.96 | 0.09 % | $ 36.6 M | USA |
 |
Athenex
ATNX
|
158 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
366 | $ 21.43 | 0.3 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
50.3 | $ 7.18 | 1.99 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
80.1 | $ 46.29 | -1.64 % | $ 1.51 B | USA |
 |
China Pharma Holdings
CPHI
|
168 | $ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Bausch Health Companies
BHC
|
172 | $ 6.9 | -0.36 % | $ 2.52 B | Canada |
 |
Organogenesis Holdings
ORGO
|
85.9 | $ 4.78 | -0.83 % | $ 629 M | USA |
 |
Lannett Company
LCI
|
127 | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
2.83 K | $ 1.8 | -6.19 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
239 | $ 3.11 | 22.92 % | $ 43.7 M | USA |
 |
Rockwell Medical
RMTI
|
28.5 | $ 0.88 | -5.3 % | $ 20.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
117 | $ 3.55 | -1.11 % | $ 4.41 M | USA |
 |
PetIQ
PETQ
|
64.9 | - | 1.64 % | $ 400 M | USA |
 |
Jupiter Wellness
JUPW
|
59.7 | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
143 | $ 12.77 | -2.78 % | $ 1.75 B | USA |
 |
ProPhase Labs
PRPH
|
30.1 | $ 0.11 | -0.35 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
204 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
49.1 | - | -4.76 % | $ 65.3 M | USA |
 |
Veru
VERU
|
179 | $ 2.4 | -0.83 % | $ 324 M | USA |
 |
OptiNose
OPTN
|
370 | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
97.2 | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
165 | $ 1.19 | -0.83 % | $ 5.13 M | USA |
 |
Tilray
TLRY
|
170 | $ 11.01 | -9.4 % | $ 6.8 B | Canada |
 |
TherapeuticsMD
TXMD
|
1.04 K | $ 1.7 | -2.86 % | $ 17.7 M | USA |
 |
Zomedica Corp.
ZOM
|
183 | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
140 | $ 11.68 | 0.29 % | $ 14.2 B | USA |